FILE PHOTO: A health official draws a dose of AstraZeneca's COVID-19 vaccine manufactured by the Serum Institute of India, at Infectious Diseases Hospital in Colombo, Sri Lanka January 29, 2021. REUTERS/Dinuka Liyanawatte/File Photo
(Reuters) - Some countries are restricting use of the AstraZeneca COVID-19 vaccine to certain age groups, or suspending use, after European and British regulators confirmed possible links to rare blood clots.
Johnson & Johnson's single-shot vaccine has also been hit by concerns over blood clots. European regulators are reviewing such cases and are expected to issue findings on April 20. U.S. federal health agencies recommended pausing its use temporarily on April 13 and a U.S. health advisory panel will meet on April 23 to discuss whether the pause should continue.
Limited time offer:
Just RM5 per month.
